chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Called 2 days after receiving injection reporting rash at injection site and spreading across chest. Itching and hurts. Being evaluated today in office at 4:20.
Pt. received flu vaccination at 1600 hrs. on 12-15-08.  At 1900 hrs. pt called nurse to say she had been coughing and felt "like there was a lump in my throat", for the past 20 minutes.  Pt denied difficulty breathing. Nurse instructed her to take 2 benadryl tabs and have husband take her to ER stat.  Pt entered ER with coughing and wheezing and c/o sore throat. tachycardia @120. Tachypenia @ 24-28. Wheezes in all lung fields. Benadryl 50 mg IVP @2020 hrs. Lab tests done. Pt. had nebulizer treatment with little relief at 2000 hrs. Pt. discharged ambulatory at 2110. Medrol dose pack as directed. Push fluids.  Potassium 10mcg PO daily, Benadryl 50 mg every 4-6 hrs X 2 doses than as needed. Return if symptoms worsen. Follow-up in clinic in 1 week.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 57-year-old male patient received BNT162b2 (BNT162B2), on 17Mar2021 as dose 2, single (Lot number: EN6294), in right arm and on 19Sep2021 as dose 3 (booster), single (Lot number: 30130BA) at the age of 56 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: OLMESARTAN HCTZ; CLOPIDOGREL; ROSUVASTATIN. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of covid-19.  Clinical Information: It was reported that patient received other medication in 2weeks Adverse event: Patient have apnea and use a cpap. he average 1-2 apnea episodes per hour. After a day or so of Paxlovid his episodes increased to approximately 12 per hour and he was awaken constantly by gasping. No such issues while away. No treatment ae. No known allergies.
Hot/sweaty, chills, vomiting, body ache, diarrhea, exhaustion, can?t sleep
Had that shot & thought that I was safe too, but now I have them/suspected vaccination failure; Had that shot & thought that I was safe too, but now I have them; This case was reported by a consumer described the occurrence of suspected vaccination failure in a adult patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows: The age at vaccination was not reported. The age group was selected as adult as per vaccine indication. The patient had that shot and thought that the patient was safe too. But now the patient had shingles. It was a total surprise to patient. This case was considered as suspected vaccination failure since the details regarding dose number, time to onset and laboratory confirmation were not reported.
Patient described rash, swelling at the site of injection the next day.    He says by Monday the rash swelled up and he contacted his prescriber.    Prescriber said the site is a  localized reaction and may be due to immunizer-dependent (i.e. immunizer injected at the wrong site).
Information has been received from a physician concerning a 17 year old patient who on 13-FEB-2008 was vaccinated with Zostavax (Oka/Merck) instead of Gardasil.  It was reported that this was due to human error and did not involve product confusion.  At the time of reporting the patient was not experiencing any known symptoms.  There was no product quality complaint.  Additional information has been requested. This is in follow-up to report(s) previously submitted on 1/26/2008.  Information has been received from a physician concerning a 17 year old patient with no pertinent medical history, or pre-existing allergies who on 13-FEB-2008 at 15:00, was vaccinated into the right arm with a first dose of ZOSTAVAX (Lot # 658863/1414U) instead of GARDASIL.  It was reported that this was due to human error and did not involve product confusion.  The patient had no illness at the time of vaccination.  On 28 FEB 2008, at 16:30, the patient received a second dose of GARDASIL (Lot # 659180/1758U), into left deltoid.  At the time of reporting the patient was not experiencing any known symptoms.  Results of diagnostic lab studies performed on an unspecified date, included the following varicella titer 1:160 and HCP negative.  There was no product quality complaint.  Further information is not expected.
This is a spontaneous report from a Pfizer-sponsored program received from a contactable consumer (patient's parent). A 16-year-old male patient received the 2nd dose of TRUMENBA, via an unspecified route of administration in left arm, on 01Nov2017 at 11:30 AM, at single dose, for immunisation. Patient was vaccinated at doctor's office. Previously the patient received the 1st dose of TRUMENBA at the end of Jul2017 and experienced really sick, fever for 2 days and sore muscles in the injected arm for 3 days. He recovered completely. The patient experienced flu like symptoms in Nov2017 with outcome of unknown, headache around 06:00 PM on 01Nov2017 with outcome of unknown for which took ADVIL, injection site rash on 02Nov2017 with outcome of not recovered, he was really tired on 02Nov2017 with outcome of not recovered, arm really sore on 01Nov2017 with outcome of not recovered.
Pt was admitted for right lower extremity swelling.  has had DVT and pulmonary embolism.  Pt found to have thrombosis of right popliteal vein.   pt following up with hematologist.
Pt. is a 16 mo old white male, who presents with the following sx, a rash. Both sisters and mother had chicken pox earlier this summer. 8 yr old sister dx'd 7-17-13 (15 days ago).
PATIENT DESCRIBES PAIN AND INABILITY TO LIFT OR ROTATE LEFT ARM IMMEDIATELY FOLLOWING THE ADMINISTRATION OF VACCINE
Injection site infection; Sensation of pain and heaviness in her arm, shoulder joint, and elbow joint; Redness at injection site; Deltoid started to swell up; Vaccine didn't go in her arm and instead ran down her arm; Vaccine didn't go in her arm and instead ran down her arm/ needle clogged or malfunctioned; Itching at injection site; Injection site swelling/deltoid started to swell up; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE INFECTION (Injection site infection), LIGAMENT SPRAIN (Deltoid started to swell up), UNDERDOSE (Vaccine didn't go in her arm and instead ran down her arm), DEVICE CONNECTION ISSUE (Vaccine didn't go in her arm and instead ran down her arm/ needle clogged or malfunctioned) and VACCINATION SITE PRURITUS (Itching at injection site) in a 36-year-old female patient who received mRNA-1273 (batch no. 036A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced LIGAMENT SPRAIN (Deltoid started to swell up), UNDERDOSE (Vaccine didn't go in her arm and instead ran down her arm), DEVICE CONNECTION ISSUE (Vaccine didn't go in her arm and instead ran down her arm/ needle clogged or malfunctioned), VACCINATION SITE PRURITUS (Itching at injection site), VACCINATION SITE SWELLING (Injection site swelling/deltoid started to swell up) and VACCINATION SITE ERYTHEMA (Redness at injection site). On an unknown date, the patient experienced VACCINATION SITE INFECTION (Injection site infection) and ARTHRALGIA (Sensation of pain and heaviness in her arm, shoulder joint, and elbow joint). At the time of the report, VACCINATION SITE INFECTION (Injection site infection), LIGAMENT SPRAIN (Deltoid started to swell up) and ARTHRALGIA (Sensation of pain and heaviness in her arm, shoulder joint, and elbow joint) outcome was unknown, UNDERDOSE (Vaccine didn't go in her arm and instead ran down her arm), DEVICE CONNECTION ISSUE (Vaccine didn't go in her arm and instead ran down her arm/ needle clogged or malfunctioned) and VACCINATION SITE ERYTHEMA (Redness at injection site) had resolved and VACCINATION SITE PRURITUS (Itching at injection site) and VACCINATION SITE SWELLING (Injection site swelling/deltoid started to swell up) had not resolved.        The action taken with mRNA-1273 (Intramuscular) was unknown.       Concomitant medications were not reported. Treatment using  antibiotic for injection site infection was reported.
I woke from sleeping feeling extremely sick and started convulsing non-stop. This went on for over an hour. I took Benadryl and it subsided with sporadic convulsions through the night and next morning. I ran a 102 temperature throughout, which was helped a little by Tylenol. Spent most of the next 24 hours sleeping.
flu like symptoms for 3+ days; Headache; Upset stomach; Sore Body; Tired; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 40 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 26Mar2021 14:00 (Lot number: ER8733) at the age of 40 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: INFLUENZA LIKE ILLNESS (non-serious) with onset 26Mar2021 15:00, outcome "recovered with sequelae" (2021), described as "flu like symptoms for 3+ days"; HEADACHE (non-serious) with onset 26Mar2021 15:00, outcome "recovered with sequelae" (2021), described as "Headache"; ABDOMINAL DISCOMFORT (non-serious) with onset 26Mar2021 15:00, outcome "recovered with sequelae" (2021), described as "Upset stomach"; PAIN (non-serious) with onset 26Mar2021 15:00, outcome "recovered with sequelae" (2021), described as "Sore Body"; FATIGUE (non-serious) with onset 26Mar2021 15:00, outcome "recovered with sequelae" (2021), described as "Tired". Therapeutic measures were not taken as a result of influenza like illness, headache, abdominal discomfort, pain.  Additional information: Facility type vaccine was at public health clinic/veterans administration facility. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient has not tested for COVID-19. No treatment for adverse events has been received. Patient did not receive any other medications within 2 weeks prior to the COVID vaccine. No known allergies and relevant history.  No follow-up attempts are possible. No further information is expected.
Began to experience fever, achiness, fatigue the day after the vaccination.  I slept a lot and took it easy--the symptoms had disappeared by the next morning.
Patient developed rash over site, as well as other areas of erythematous, patchy lesions over legs and arms. No truncal or oral involvement.
Approximately 24 hours after receiving the vaccination, I rapidly developed pain and tenderness on the anterior side of my left armpit. This spread to the posterior side as well later that evening. The area is very tender to the touch and feels bruised. Without any external pressure applied, there remains a near constant ache/pain, at times a 6 on a pain scale of 1-10. Ibuprofen does provide some relief, but not complete. The pain continues at time of reporting, some 68 hours post vaccination.
PATIENT RECIEVED THE BIVALENT INSTEAD OF THE PRIMARY DOSE , IT WAS THEIR FIRST VACCINE
1) No symptons on the day of injection at injection site or otherwise.  1.) Within the first week had extensive vitiligo spread on both hands.  The palms of both hands show darkened pigmentation from the inside knuckles to tips of fingers, along with scattered patches of vitiligo.  Had a mild case of vitiligo on both hands, lips, and under the nostrils for which I had pictures taken between 2015 and 2016, and one picture of right hand (in 2017)--which was the most affected hand--but was in a state of re-pigmentation between 2015-2016 so no new pictures were taken and was dormant from 2017 to 2021 prior to the vaccine.  2) Dark streaks appeared on nails on the hands and feet with complete darkening--and in two cases blackening-- of the big toe nail on the left foot and 2nd toe nail on the right foot.  Both nails have lifted from the nail bed and have either come off (2nd toe on right) or is still lifting itself (big toe on the left foot).  Nails are also especially brittle and developed cracks/lines/crevices in the nails.  3)  Hair became especially dry, brittle and broke off in large chunks within the first month.  It lacked any form of moisture that it used to have. Resorted to discontinuing chemical relaxers in November 2021, and resorted to using protective styles (cap-weaves, wigs, etc.,) that avoided having to comb through the hair in hopes of limiting the breakage, because the hair loss exceeded 50-60% of pre-vaccine lengths.  Took 2nd dose of the Moderna Covid 19 vaccine on 8/6/2021, Lot No. 001B21A, at the same pharmacy don't recall time but guess afternoon.  Shot was by injection, in the left arm.  Again i had no specific reactions to the shot at the injection site similar to the 1st dose.  No headches.  However, the other adverse reactions of vitiligo spread, impact on nails and hai-- as noted before continued--and has continued to spread.  The patches on the both hands, lips and under the nostrils have continued to spread, and I recently noted small vitiligo patches on each elbow on 7/2/22; but unsure of exactly when those developed.
Symptoms: (have now persisted for over a month since the vaccination on Oct. 22, 2008). Include: deep aching in left upper arm, radiating into shoulder, especially when arm is at rest, such as when reading or driving; pain into left side of neck and chest (mimicks angina); difficulty placing left arm into coat sleeve due to decrease range of motion in left shoulder; no significant relief of discomfort after using Aleve, Ibuprofen or Ben Gay
fever 100 - 102, body aches, chills, sever nighttime sweating,  intermittent nausea, severe headache, fatigue, face feeling flush for 48hours beginning approximately 3 hours post second vaccination treated with acetaminophen, ibuprofen, fluids and rest
This case was reported by a pharmacist via call center representative and described the occurrence of extensive swelling of vaccinated limb in a 61-year-old female patient who received Shingrix (batch number K2ZY4, expiry date 13th April 2021) for prophylaxis. On 14th December 2018, the patient received the 2nd dose of Shingrix (intramuscular). In December 2018, less than a week after receiving Shingrix, the patient experienced extensive swelling of vaccinated limb and burning sensation. On an unknown date, the outcome of the extensive swelling of vaccinated limb and burning sensation were unknown. It was unknown if the reporter considered the extensive swelling of vaccinated limb and burning sensation to be related to Shingrix. Additional details were reported as follows: The patient received Shingrix vaccine on unknown deltoid. The reporter stated that the patient developed a 6 inch by 4 inch area of swelling in the vaccinated arm after receiving Shingrix vaccine. The patient also mentioned that she had a burning feeling in her arm. The reporter gave consent to follow up.
Patient was transferred from facility to facility on 10/11/21 for acute hypoxemic respiratory failure due to covid-19 pneumonia.  Patient tested positive for covid on 9/28/21 and is fully vaccinated.  At facility, course was complicated by MSSA VAP, was appropriately treated with antibiotics. Chest x ray from 11/5 showed increased LLB opacification, likely superimposed aspiration. 7 day course for MSSA and 5 day course for c/f aspiration PNA was completed. Patient was discharged on 11/18/21.
Tachycardia & within 15 minutes of administration but subsided 30-40 minutes after vaccination
Seizure lasting approx. 1 minute. Lips turned blue. Stiff muscles. Patient visited the ER. Referral to neurologist/primary doctor for follow up.
Pt developed lightheadedness, SOB approx 15min after vaccination. Pt discharged in stable condition.  BP 143/80 HR 100, normal rhythm on auscultation.  RR 20, unlabored.  SpO2 97% RA.
Patient presented for her second COVID vaccine on 04/21/21 and described events following her first vaccine on 03/24/21. She reported that about 30 minutes after her vaccine she felt the vaccine "moving through her arm". She stated her left arm, hand, and fingers were tingling all the way up to her neck.  She did not feel short of breath but did report that her tongue felt "thick".  She also reported that her brain was "foggy" and she had a metallic taste in her mouth.  These sensations lasted throughout the day and evening and she was "fine" the next day.  She did not discuss any of her symptoms with a doctor. She states she had hesitations about getting the second vaccine. We discussed that due to her side effects we would not recommend getting the second vaccine at this time and that she could discuss further with her primary care if needed. She was agreeable to this.
Arm is sore; Headache; Swollen at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm is sore), HEADACHE (Headache) and VACCINATION SITE SWELLING (Swollen at the injection site) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included GABAPENTIN, ATENOLOL, CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]), OMEPRAZOLE MAGNESIUM (PRILOSEC [OMEPRAZOLE MAGNESIUM]), METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE MONOHYDRATE (JANUMET) and GLIMEPIRIDE for an unknown indication.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Arm is sore), HEADACHE (Headache) and VACCINATION SITE SWELLING (Swollen at the injection site). At the time of the report, PAIN IN EXTREMITY (Arm is sore), HEADACHE (Headache) and VACCINATION SITE SWELLING (Swollen at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Most recent FOLLOW-UP information incorporated above includes: On 21-Jan-2021: No specific follow-up information recorded.
Sore muscles in arm for two weeks.  Soreness increasing from day of shot for weeks.  Muscles throughout body became sore and weak.  Fatique increasingly becoming worse within days of shots and continued to worsen to severe fatigue within 1 week of shots and continues to remain today. Dizziness & nausea within 2 weeks of shots.  Continues off & on regularly.  Mind cloudy and memorory fadding within 1 month of shot.  Continued to worsen and effect daily routine to point of missing work, unable to function as normal causing and to the point of depression.  All symptoms continue now.  Seeing various doctors to treat symptoms.  Various tests and treatment of symptoms continue to date.  Cause possibly due to previous Anthrax Vaccine the effected immune sysmtem and was complicated and compromised health by recent vaccines.  There is a previous Vaers for Anthrax Vaccine on filed in previous years.
received a late second dose / first dose was administered on 03Mar2020 and the second dose on 31Mar2021; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 35-year-old male patient who received HBV (Engerix B) for prophylaxis.   Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Engerix B (1st dose received on 3rd March 2020.).   On 31st March 2021, the patient received the 2nd dose of Engerix B and Engerix B Pre-Filled Syringe Device. On 31st March 2021, unknown after receiving Engerix B and Engerix B Pre-Filled Syringe Device, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The patient received the 2nd dose of Engerix B vaccine, more than recommended interval, which was lengthening of the vaccination schedule. No further information was reported. The reporter consented to follow up.
Chills, nausea, headache, fatigue, fever, arm soreness with pain in armpit,
COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66-year-old male patient received BNT162b2 (BNT162B2), on 27Jan2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 65 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Cancer" (unspecified if ongoing). Concomitant medication(s) included: IMBRUVICA, start date: 14Nov2019, stop date: 06Jun2022. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jun2022, outcome "unknown" and all described as "COVID-19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Jun2022) Positive; (Jun2022) Negative, notes: testing Negative two days; (Jun2022) Negative. Therapeutic measures were taken as a result of covid-19. Clinical course: Adverse event Four days after stopping paxlovid, and after testing negative two days following last dose of paxlovid, I tested positive for COVID again. Symptoms returned the following day. Patient received Paxlovid (start date: 07Jun2022, stop date: 12Jun2022) as Treatment of COVID-19. No known allergies. No treatment ae.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Severe chills and shaking, fever of 102 lethargic and unable to move around.
Patient stated about 24 hours after receiving his 1st Pfizer dose, he got up to use the bathroom and felt dizzy.  He woke up laying on the bathroom floor and was mildly shaking - was concerned he may have had a seizure.  He believes he was "out" for just a few minutes.  No reports of prior fainting  or seizure episodes.  Patient did report marijuana usage.  Patient has not seen a Dr since the incident and is feeling fine currently.  I indicated he should follow-up with Dr before receiving a 2nd dose.
Developed rash on arms and back 3 days after receiving Hepatitis A vaccine and Thyphoid vaccine. Rash progressed to buttocks, groin and forearms. Given Zyrtec 10mg one p.o. x 7 days. To return to the clinic after 3 days of treatment.